Pharmaceutical Technology

JUNE 16, 2023

Since some of the patients with major clinical depression do not respond sufficiently to one or more antidepressants, there is a need for new treatments, said Buntinx. Due to this, adjunctive treatments are used as part of a patient’s treatment regimen. While the drug is marketed in other countries, it is not registered in the US.

Food and Drug Administration 52

Food and Drug Administration Side effects Safety Recruitment 52

Pharmaceutical Technology

JULY 28, 2022

Discontinuation or non-adherence to antipsychotic treatment is the most common cause of relapse in patients diagnosed with schizophrenia. As such, patients are typically offered continuous antipsychotic pharmacotherapy to prevent recurring episodes of psychosis. and 82.7%, respectively, of patients using oral aripiprazole.

Prescription 98

Prescription Side effects Patients Management 98

pharmaphorum

JUNE 23, 2022

The deal comes a year after Intellia and partner Regeneron reported promising results from the first clinical trial of a drug used to edit the genomes of cells within the body, in patients with rare disease ATTR amyloidosis.

Side effects 89

Side effects Pharma Marketing Patients 89

pharmaphorum

AUGUST 19, 2022

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of opioid drugs. If all goes well, the aim is to bring resiniferatoxin to market in 2025.

Side effects 52

Side effects Recruitment Patients Safety 52

pharmaphorum

SEPTEMBER 15, 2022

In the aftermath of that results, it modified the design of its second phase 3 trial – TRANQUILITY 2 – to increase the number if patients enrolled and add in tear production measured suing the Schirmer test as a co-primary endpoint. Sales were nevertheless solid at $468 million and $1.29 billion respectively last year.

FDA 52

FDA Side effects Prospecting Patients 52

pharmaphorum

JULY 11, 2022

The company had been eyeing a possible regulatory filing for fitusiran this year, but has now set back the timeline – possibly until 2024 – while it gathers data on the revised dosing schedule, in the hope of maintaining efficacy with fewer clotting side effects.

Engineering 52

Engineering Side effects Competition Sales 52

pharmaphorum

OCTOBER 10, 2022

month mPFS with Keytruda plus chemo, with fewer side effects. That approval was in melanoma, a much smaller patient population than NSCLC, although BMS is already testing Opdualag in NSCLC and other indications, including colorectal cancer, and has predicted it could make annual sales of $4 billion by the end of the decade.

Side effects 58

Side effects Sales Marketing FDA 58

European Pharmaceutical Review

AUGUST 3, 2023

This study has been hailed as a breakthrough as the data show that Leqembi achieved a 27 percent reduction in the progression of Alzheimer’s, provided patients were treated early following the diagnosis of the disease. Under a “usual” EMA assessment timetable, it is likely that Leqembi would not be authorised before Q2 2024.

Food and Drug Administration 52

Food and Drug Administration Medicine FDA Marketing 52

pharmaphorum

JULY 26, 2022

Other late-stage trials on the go include BROOKLYN, which is enrolling adults with HeFH whose LDL cholesterol is not adequately controlled despite being on maximally tolerated lipid-modifying therapies, and a cardiovascular outcomes study in ASCVD patients called PREVAIL. So why will obicetrapib avoid the pitfalls of its predecessors?

Side effects 52

Side effects Safety Pharma Patients 52

Medico Reach

FEBRUARY 8, 2023

billion during 2020-2024. The Emergence of the Pharmacovigilance Market Medicines and vaccines often have unwanted and severe side effects. Such results call for stringent vigilance on the medicines quality and after-effects, nudging the emergence of the pharmacovigilance market. from 2023 to 2030.

Pharma 52

Pharma Medicine Marketing Prospecting 52

Evolve Your Success

FEBRUARY 13, 2024

— Watch the episode here Listen to the podcast here Surviving Cancer And Making An Impact To Cancer Patients’ Lives With Rob Ciaramitaro In this episode, we have with us another special guest and he goes by the name of Rob Ciaramitaro. Diagnostic products can change when patients discover their diseases.

Patients 64

Patients Sales Medical sales Doctors 64

pharmaphorum

DECEMBER 5, 2022

A medium or high dose of its lead, CD19-targeting CAR-NK therapy candidate NKX19 achieved complete responses in seven out of 10 patients with relapsed or refractory non-Hodgkin lymphoma (NHL), driving their cancer into remission. Those will get underway in 2024.

Side effects 94

Side effects Safety Patients Leads 94

pharmaphorum

SEPTEMBER 14, 2022

After years of stagnation in the treatment of neurodegenerative disorder amyotrophic lateral sclerosis (ALS), patients in the US could soon have two new treatment options – but their pricing is already raising red flags.

Side effects 63

Side effects FDA Medical Patients 63

PM360

APRIL 22, 2024

For instance, they can report back on unmet medical needs in the market and on prescriber or patient experiences with the standard of care or the product being utilized. Ideally, insights from MSL activities lead to better evidence and more successful development programs and patient outcomes.

Education 52

Education Customer Relationship Management Medical science Medical 52

Pharmaceutical Technology

FEBRUARY 17, 2023

In January, amidst calls to improve patient safety by optimizing licensed drug formulations, the FDA released a draft guidance that signalled a departure from the most commonly used method of identifying a new therapy’s ideal dosage. For this approach, a “3+3” model is used where a study enrolls three patients into a given dose cohort.

FDA 115

FDA Side effects Pharmacology Patients 115

Pharmaceutical Technology

JUNE 20, 2023

GlobalData forecasts that the market for AI platforms for the entire healthcare industry will reach $4.3bn by 2024, up from $1.5bn in 2019 [i]. Consent documents often describe technical medical conditions and regulatory bodies are increasing pressure on sponsors to ensure that patient-facing information can be easily understood by patients.

Electronics 52

Electronics Medical Healthcare Healthcare 52